"10.1371_journal.pone.0035436","plos one","2012-04-16T00:00:00Z","Shane Zaidi; Martin McLaughlin; Shreerang A Bhide; Suzanne A Eccles; Paul Workman; Christopher M Nutting; Robert A Huddart; Kevin J Harrington","Targeted Therapy Team, Institute of Cancer Research, Chester Beatty Laboratories, London, United Kingdom; Tumour Biology and Metastasis Team, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom; Signal Transduction and Molecular Pharmacology Team, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; The Royal Marsden Hospital, Sutton, United Kingdom","Conceived and designed the experiments: SZ MM KJH. Performed the experiments: SZ MM. Analyzed the data: SZ MM SAB SAE PW CMN RAH KJH. Wrote the paper: SZ MM SAE PW CMN RAH KJH.","SZ, MM, SAB, SAE, PW and KJH are or have been employees or students of The Institute of Cancer Research. Intellectual property from the research collaboration with Vernalis Ltd. on HSP90 inhibitors was licensed from The Institute of Cancer Research to Vernalis Ltd. and Novartis. The Institute of Cancer Research has benefited from this and requires its employees to declare this potential conflict of interest. SAE: consultant, Vernalis Ltd. PW: commercial research grant, Vernalis Ltd. (not used for the funding of this study); consultant, Novartis. CMN and RAH declare no conflicts of interest. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guidelines for authors.","2012","04","Shane Zaidi","SZ",8,TRUE,3,2,8,7,TRUE,TRUE,FALSE,0,NA,FALSE
